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Abstract
The objectives of these studies were to investigate and compare solid lipid nanoparticles (SLNs) of
two anthracyclines, idarubicin (IDA) and doxorubicin (DOX), against Pgp-mediated multiple drug
resistance (MDR.) in-vitro and in-vivo using different human and murine cancer cell models. IDA
and DOX SLNs were developed from warm microemulsion precursors comprising emulsifying wax
as the oil phase, and polyoxyl 20-stearyl ether (Brij 78) and D-alpha-tocopheryl polyethylene glycol
succinate (Vitamin E TPGS) as the surfactants. Anionic ion-pairing agents, sodium
taurodeoxycholate (STDC) and sodium tetradecyl sulfate (STS), were used to neutralize the charges
of the cationic anthracyclines and enhance entrapment of the drugs in the SLN. The in-vitro
cytotoxicity results showed that the IC50 value of DOX NPs was 9-fold lower than that of free DOX
solution in resistant P388/ADR cell line. In contrast, free IDA had comparable IC50 values as IDA
NPs in Pgp-overexpressing P388/ADR and HCT-15 cells. In the in-vivo P388/ADR leukemia mouse
model, the median survival time of DOX NPs was significantly greater than that of free DOX, and
controls. In contrast, free IDA was equally as effective as IDA NPs in P388 and Pgp-overexpressing
HCT-15 mouse tumor models. The cell uptake of IDA formulated as free IDA and IDA NPs was
comparable in Pgp-overexpressing cells. In conclusion, DOX NPs could overcome Pgp-mediated
MDR both in-vitro in P388/ADR leukemia cells and in-vivo in the murine leukemia mouse model.
The present study suggests that our SLNs may offer potential to deliver anticancer drugs for the
treatment of Pgp-mediated MDR in leukemia; however, selection of target drug may be very
important.
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Anthracyclines rank among the most effective anticancer drugs ever developed [1]. The
cytotoxicity of anthracyclines is generally due to their ability to diffuse across the cell
membrane, intercalate between DNA base pairs, and target topoisomerase II [2]. Doxorubicin
(DOX, Figure 1A) is one of the oldest anthracyclines and is commonly used to treat leukemia,
Hodgkin's lymphoma, bladder and breast cancers. Idarubicin (IDA, 4-demethoxydaunorubicin,
Figure 1A), a synthetic analog of daunorubicin (DNR), was approved by the US FDA in 1990.
It is mainly used to treat acute myelogenous leukemia (AML) and chronic lymphocytic
leukemia (CLL) [3]. The absence of the methoxy group at position 4 of IDA results in
significantly enhanced lipophilicity [4], which results in faster cellular uptake, superior DNA-
binding capacity, and consequently greater cytotoxicity compared to DOX and DNR.
After initial treatment with anthracyclines, many patients achieve a complete remission;
however, about 70% of the patients eventually experience a relapse of the disease. A major
cause of treatment failure in patients with leukemia is the development of MDR. Different
MDR mechanisms have been characterized [5]. P-glycoprotein (Pgp), a membrane transporter
encoded by the MDR1 gene, is responsible for the efflux of anthracyclines used in the treatment
of leukemia. Goasguen et al. [6] reported the correlation of complete remission, relapse rate
and lymphoblast Pgp expression in a study involving 23 adult patients with acute lymphoblastic
leukemia (ALL). In this study, complete remission was achieved in 5/9 Pgp+ patients compared
to 13/14 of Pgp- patients (56 vs. 93%). During the follow-up period, relapse occurred in all
Pgp+ patients that had initially shown complete remission compared to 6/13 Pgp- patients
(100% vs. 46%), which indicated that the presence of a critical level of functional Pgp in
leukemic lymphoblasts was potentially an important determinant of response to chemotherapy
treatment. To overcome Pgp-mediated MDR in leukemia, various Pgp inhibitors, such as
quinine, cyclosporine A, and PSC 833, have been developed and co-administered with
anticancer agents [7–9]. This approach resulted in significant improvement in anthracycline
tumor therapy. However, the co-administration of Pgp inhibitors with anticancer drugs often
results in enhanced drug toxicity due to the non-specific inhibition of Pgp that leads to alteration
of drug elimination pathways, e.g. in liver or kidney [10].
The use of small particle delivery systems, such as liposomes and nanoparticles (NPs), has
been shown experimentally to improve cancer treatment as carriers of conventional
chemotherapeutic agents [11]. The utility of nano-scale delivery systems is based on their
potential to enhance drug delivery into tumor tissues (e.g. EPR effect), while minimizing
systemic exposure and thus enhancing drug efficacy and reducing non-specific toxicity. These
colloidal delivery systems have also been shown to increase the circulation time of drugs in
the blood, thereby increasing the ability of drugs to reach their sites of action. The efficacy of
these systems has been reported utilizing numerous cancer drugs including paclitaxel,
tamoxifen, and anthracyclines. For example, Gian and colleagues [12] developed IDA SLNs
and determined the pharmacokinetics after duodenal administration in rats. The authors found
that duodenally administered SLNs increased IDA exposure and the area under the curve
(AUC) of concentration versus time profiles. In addition, the elimination half-life of IDA SLNs
was 21-fold and 30-fold higher, respectively, as compared to a solution of free IDA.
SLNs have attracted increasing attention during recent years. The major advantages of these
SLNs include high drug loading and entrapment efficiency, improved drug stability, and
potential biocompatibility since the SLNs use lipids [13]. Due to the fact that many
anthracyclines have cationic moieties, counter-ions have been employed to facilitate the
entrapment of the drug in SLNs. The Gasco group [14] showed that either decyl phosphate or
hexadecyl phosphate could form ion-pairs with DOX or IDA in SLNs containing stearic acid
and egg lecithin. The resulting ion-pair complexes increased the lipophilicity of IDA and DOX,
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which resulted in an increase in the apparent partition coefficient between stearic acid and
water. SLNs containing these lipophilic ion-pairs carried payloads of DOX and IDA at up to
7% and 8.4% (w/w), respectively. Similarly, an anionic hydrolyzed polymer of epoxidized
soybean oil (HPESO) was used by Wong and co-workers [15] to complex with cationic DOX.
The resulting complex was then dispersed together with a lipid to form DOX SLNs.
In the present studies, an optimized ion-pairing strategy was performed to entrap IDA and DOX
in SLNs. Different counter-ions were employed to ion-pair with IDA or DOX and together
incorporated into SLN formulations. The main objectives of these studies were: 1) to
investigate and compare IDA SLNs and DOX SLNs against Pgp-mediated MDR in-vitro and
in-vivo; and 2) to test the feasibility of the SLNs as potential drug carriers for MDR-related
cancer therapy. IDA and DOX SLNs were engineered from warm microemulsion precursors.
The SLN formulations versus free drug solutions were tested in different mouse and human




Idarubicin hydrochloride was obtained from Synbias Pharma Ltd (Donetsk, Ukraine).
Doxorubicin hydrochloride, sodium taurodeoxycholate (STDC, >97% pure), dextran sulfate
sodium (DS, MWs approx. 5,000 and 8,000), and protease inhibitor cocktail were purchased
from Sigma (St. Louis, MO, USA). Emulsifying wax (E-wax), and sodium tetradecyl sulfate
(STS) were from Spectrum Chemicals (New Brunswick, NJ, USA). Polyoxyl 20-stearyl ether
(Brij 78) was obtained from Uniqema (Wilmington, DE, USA). DSPE-PEG3000 (25 mg/mL
in chloroform) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). RIPA buffer
(containing 25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate,
0.1% SDS), and the bicinchoninic acid protein assay kit were from Thermo Scientific
(Rockford, IL, USA). Mouse monoclonal antibody Mdr-1 (D-11), β-actin mouse monoclonal
antibody, and goat anti-mouse IgG-HRP were bought from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Vitamin E TPGS was generously provided by Eastman Chemical Co.
(Kingsport, TN, USA). Dextran sulfate sodium (MW approx. 2,500) was obtained from ABCR
GmbH & Co. (Karlsruhe, Germany).
Human colorectal carcinoma cell line HCT-15, human breast cancer cell line MDA-MB-468,
and human promyelocytic leukemia cell line HL-60 were purchased from ATCC (Manassas,
VA, USA). The resistant cells HL-60/VCR and HL-60/ADR were kindly provided by Dr. Baer
(Roswell Park Cancer Institute, Buffalo, NY, USA). Murine leukemia P388 and P388/ADR
cell lines were obtained from the NCI (Frederick, MD, USA). The MDA-MB-468 cell line was
maintained in DMEM and all the other cell lines were cultured in RPMI-1640 medium
(Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS) (ATCC, Manassas,
VA, USA) and antibiotics at 37°C in 5% CO2 humidified atmosphere.
Preparation of IDA or DOX Ion-Pair Complex
To neutralize the charges of cationic anthracyclines and enhance drug entrapment, an ion-pair
complex was prepared using a co-precipitation method. STDC, dextran sulfate sodium (MWs
approx. 2,500, 5,000, and 8,000), and STS were investigated as potential counter-ions. The
amount of IDA or DOX used was calculated as the base form throughout the experiments. One
hundred (100) µL of 1 mg/mL IDA or DOX in water was aliquoted into a series of 1.5 mL
centrifuge tubes, and then 100 µL of different concentrations of ion-pairing aqueous solution
was added to the tubes. The tubes were shaken for 5 min with the speed of 40 rpm, and
centrifuged for another 5 min with the speed of 1,530 × g. The concentrations of IDA or DOX
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in the supernatant were measured using a spectrophotometer. The percentage of the drug ion-
paired with counter-ions was calculated as follows:
Preparation of NPs from Microemulsion Precursors
Microemulsion precursors were prepared as reported by Mumper et al. [16]. Briefly, 2 mg of
E-wax as the oil phase, 2.3 mg of Brij 78, and 3.0 mg of Vitamin E TPGS as the surfactants
were accurately weighed out into a 7 mL glass vial. The vial was heated to 65°C to melt the
oil and surfactants while stirring. The IDA or DOX ion-pair complex precipitate was dissolved
in ethanol and transferred to the vial containing the oil and surfactant mixture. Residual ethanol
was evaporated under a stream of nitrogen gas, and then preheated deionized water was added
to obtain a final volume of 1 mL. Oil-in-water microemulsions formed spontaneously at this
elevated temperature. Upon direct cooling of the warm microemulsions to room temperature,
clear SLN suspensions were formed. Polyethylene glycol coated NPs (PEG NPs) were also
engineered as described above, except that 16 µL of a DSPE-PEG3000 stock solution in water
(10 mg/mL) was added to the vial five min before cooling. Blank NPs were prepared in the
same manner except that the IDA or DOX, and ion-pairing agents were omitted.
Characterization of NP Formulations
Photon Correlation Spectroscopy—The average particle size and polydispersity index
(PI) of IDA or DOX NPs were determined by photon correlation spectroscopy (PCS) using a
Coulter N5 Plus Sub-Micron Particle Sizer (Beckman Coulter, Miami, FL, USA) at a fixed
angle of 90° and a temperature of 25°C. Prior to size determination, NP suspensions were
diluted in deionized water to ensure light scattering intensity within the required range of the
instrument (5 × 104 to 1 × 106 counts/s). Each sample was analyzed in triplicate.
Zeta Potential Determination—To determine the zeta potential, NP samples were diluted
1:100 (v/v) with 10 mM PBS (pH 7.4) and placed in the dip cell of Zetasizer Nano Z (Malvern
Instruments, Westborough, MA, USA). Each sample was analyzed in quintuplicate.
% Entrapment of NPs—To determine % entrapment of IDA or DOX in the NPs, Microcon
Ultracel YM-100 Centrifugal Filtration Devices (MW cut-off 100 kDa) (Millipore, Billerica,
MA, USA) were used. A fixed volume (300 µL) of the drug NP formulations was added to a
Microcon tube and spun at 14,000 × g at 25°C for 30 min. The collected filtrate in the tube was
labeled as “free drug filtrate”. Then the filter apparatus was removed, inverted, and transferred
to a new Microcon tube. Drug NPs were spun at 6,000 × g at 25°C for 4 min and collected in
this tube labeled as “drug in NPs”. Concentrations of IDA or DOX were determined using a
Synergy 2 Multi-Detection Microplate Reader (BioTek, Winooski, VT, USA) at the
wavelengths of 483 and 487 nm, respectively. The % entrapment was calculated as follows:
Western Blot Analysis
Cellular content of the Mdr-1/Pgp transporter molecule was detected by western blot analysis
in P388, P388/ADR, and HCT-15 cell lines. Briefly, 107 cells were lysed in 0.3 mL RIPA
buffer, including protease inhibitor cocktail. The quantification of the protein content was
performed with the bicinchoninic acid (BCA) protein assay kit. For immunoblotting, 40–60
µg of total protein extract was mixed with Laemmli sample buffer (Bio-Rad Laboratories,
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Hercules, CA, USA) and transferred to a 10% polyacrylamide gel. Gel electrophoresis was
performed with a Mini Protean® 3 Cell (Bio-Rad Laboratories, Hercules, CA, USA) applying
100V for 100 min. After electrophoresis, proteins were blotted to a PVDF membrane (100V
for 1 hr) using a Mini Trans-Blot® Cell (Bio-Rad Laboratories, Hercules, CA, USA). The
membrane was blocked for 1 hr with PBS-T (phosphate buffered saline containing 0.05%
Tween 20) with 5% nonfat milk. After washing three times with PBS-T, the membrane was
incubated at 4 °C overnight with the primary mouse monoclonal antibody Mdr-1, diluted 1:200
(v/v) in PBS-T with 5% nonfat milk. β-actin was used as a loading control by staining with β-
actin mouse monoclonal antibody at a dilution of 1:2000 (v/v). After incubation with the first
antibody, the membrane was washed with PBS-T three times and then incubated with the
secondary goat anti-mouse IgG-HRP diluted 1:2000 (v/v) for 1 hr at room temperature. The
membrane was then washed, and Pgp and β-actin detection were performed with the ECL
Detection VersaDoc™ Imaging System (Bio-Rad Laboratories, Hercules, CA, USA). The
molecular weight was identified using the Precision Plus Protein™ Standard Dual Color (Bio-
Rad Laboratories, Hercules, CA, USA).
In-Vitro Cytotoxicity Assay
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay was utilized
to assess cytotoxicity of the NPs [17]. Viable cells were counted by trypan blue staining (>90%
cell viability for experiments) and seeded in 96-well plates at 8,000 cells/100 µL growth
medium. Serial dilutions of DOX or IDA formulations were added to the plate (100 µL/well)
at 37°C in 5% CO2 for 48 hr. The cells were then incubated with MTT stock solution (5 mg/
mL in PBS; pH 7.4) at 37°C for 4 hr. Cell suspensions were spun down for 10 min at 1,000 ×
g (this step was not required for adherent cell lines). The medium was then removed and the
converted dye was solubilized with the addition of DMSO. The absorbance was measured
using the Synergy 2 Multi-Detection Microplate Reader at 570 nm, and the concentration of
drug that inhibited cell survival by 50% (IC50) was determined from cell survival plots.
Cellular Uptake of Free IDA and IDA NPs
Cellular uptake of free IDA and IDA NPs were performed in HL-60 and HL-60/VCR cell lines.
Different dilutions of each test article were added to a 12-well plate (7.5×105 cells/well). After
4 hr incubation at 37°C in 5% CO2, cells were transferred to 15 mL graduated tubes and
centrifuged. The medium was then aspirated and replaced with fresh medium. Cell-associated
fluorescence was read using the Synergy 2 Multi-Detection Microplate Reader at the excitation
and emission wavelengths of 485 ± 20 and 545 ± 10 nm, respectively.
Visualizing Cellular Uptake of IDA and DOX NPs
MDA-MB-468 cells were first plated onto glass slides, then aliquots of free DOX or IDA, and
their NPs (10 µL) were dispersed on glass slides and covered with coverslips. The cellular
uptake of free drug and drug NPs was visualized with CytoViva Microscope System (Auburn,
AL) at room temperature.
In-Vivo Animal Efficacy Studies
Five-week-old male CD2F1 or six-week-old male athymic NCr-nu/nu mice from NCI-
Frederick Animal Production Area (Frederick, MD, USA) were used for the studies. All mice
were on a 12-hr light/dark cycle and sterilized rodent diet (Harlan-Teklad TD8656) ad
libitum. The animal experiments complied with the rules set forth in the NIH Guide for the
Care and Use of Laboratory Animals. In total, three separate in-vivo studies were performed;
the first two studies using IDA formulations and the third study using DOX formulations.
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Study 1 was to treat with free IDA and IDA NPs in male athymic nude mice which were
subcutaneously (s.c.) implanted with HCT-15 human colon tumor cells. Study 1 consisted of
a vehicle-treated control group (saline) having 10 mice, and 9 treatment groups with 10 mice
each for a total of 100 mice. Free IDA and IDA-STS PEG NPs were administered intravenously
(i.v.) at doses of 2.25, 1.5, 1.0, and 0.67 mg/kg/injection on a q4d × 3 treatment schedule. Study
2 was designed to treat with free IDA and IDA NPs in male CD2F1 mice which were i.v.
implanted with P388 murine leukemia cells. Study 2 consisted of a vehicle-treated control
group (saline) having 10 mice, and 12 treatment groups with 6 mice each for a total of 82 mice.
Free IDA, IDA-STS NPs and IDA-STS PEG NPs were each i.v. injected at doses of 2.25, 1.5,
1.0, and 0.67 mg/kg/injection on a q4d × 3 treatment schedule. The experimental procedures
of studies 1–2 were similar to the following study 3 of DOX formulations.
Study 3 was designed to treat with free DOX and DOX NPs in male CD2F1 mice in which
105 P388/ADR murine leukemia cells were implanted intraperitoneally (i.p). The day of tumor
cell inoculation was designated as Day 0. The animals were randomly assigned to the various
treatment groups on Day 1 after tumor implantation. The experiment consisted of a vehicle-
treated control (saline) having 10 mice, and 12 treatment groups with 6 mice each for a total
of 82 mice at the start of treatment on Day 1. Free DOX, DOX NPs, DOX PEG NPs, and blank
NPs were each injected i.p. at doses of 8.0, 5.3, and 3.5 mg/kg/injection on a q4d × 3 treatment
schedule. Doses were administered by exact body weight using an injection volume of 0.1 mL/
10 g of body weight. The number of 25 day survivors, median day of death, and Increase in
Life-Span (ILS) based on median day of death were recorded. The percentage of ILS was
calculated as follows:
Statistical Analysis
For the animal efficacy studies, statistical analysis was conducted using a life table analysis
(stratified Kaplan-Meier estimation followed by the Mantel-Haenszel log-rank test). A life
table analysis allowed the data between groups using the animals that did not reach the endpoint
to be compared by censoring them. When appropriate, the data sets were analyzed using
Student’s t-test. Differences were considered significant if p < 0.05.
RESULTS
Preparation of IDA Ion-Pair Complex
To facilitate the entrapment of positively charged IDA or DOX in the oil phase, several
negatively charged ion-pairing agents were identified and tested, such as STDC, DS2500,
DS5000, DS8000, and STS. Figure 2 shows the % IDA ion-paired with STS at different IDA/
STS molar ratios in aqueous solution. At IDA and STS molar ratios of 1:2, 1:1.75, 1:1.5, and
1:1.25, greater than 95% of IDA was ion-paired with STS. As more or less STS were added,
the % IDA formed in ion-pair complex decreased as indicated by the bell-shaped curve. The
optimal IDA/STS molar ratio was 1:1.25, at which 98.0 ± 0.1% of IDA ion-paired with STS.
Therefore, this IDA/STS molar ratio was used for future IDA-STS NP preparations. Figure 1B
displays the structure of the IDA-STS or DOX-STS complex. The negatively charged sulfate
group on STS attracts the positively charged amino sugar moiety on IDA or DOX in roughly
a 1:1 molar ratio. Furthermore, the long alkyl chain on STS increases the lipophilicity of the
complex thereby facilitating the entrapment of IDA or DOX in the oil phase. The optimal
weight ratios of IDA/DS2500, IDA/DS5000, IDA/D8000 were 2.94:1, 3.48:1, 2.49:1,
respctively, at which more than 90% IDA ion-paired with all various DS counter-ions.
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However, probably due to the large size of the DS molecule and its relative hydrophilicity, the
loading of the IDA-DS or DOX-DS ion-pair complex in the oil phase was low. The optimal
IDA/STDC molar ratio was 1:1. Therefore, STDC and STS were selected as ion-pairing agents
in our studies. The optimal molar ratio of DOX and STS was 1:1.25 (data not shown).
Characterization of NP Formulations
Table 1 reports the average particle size, PI, % entrapment, and zeta potential values for IDA
and DOX NPs. The average particle size of either IDA NPs or DOX NPs was less than or
around 100 nm. PI values were small (< 0.3) indicating uniform and mono-disperse NP
suspensions. Entrapment efficiencies were also high (> 80%) and zeta potential ranged from
−5 to −15 mV.
More concentrated IDA-STDC NPs, from 240 µg up to 600 µg IDA/mL, were also successfully
engineered by simply decreasing the volume of aqueous phase in the warm o/w microemulsion
while keeping the composition of oil phase (oil + surfactant + drug) constant (Figure 3). No
significant changes of particle size and PI values were observed between different concentrated
NP formulations. This provides a very convenient method for preparing concentrated NP
preparations by simple adding less water during the formation of the warm oil-in-water
microemulsions. In a similar manner, DOX-STS NPs could also be prepared from 200 µg up
to 800 µg DOX/mL without significant change in particle size and PI values (data not shown).
Western Blot Analysis
Expression of Pgp levels in P388, P388/ADR, and HCT-15 cell lines was detected using
western blot analysis. As shown in Figure 4, P388/ADR and HCT-15 cell lines overexpressed
Pgp, while P388 cells did not demonstrate any Pgp-specific signal. This was consistent with
the documented information on Pgp expression level for these cell lines. β-actin was used as
the loading control. The Pgp expressions of P388/ADR and HCT-15 cells were comparable
when normalized to β-actin.
In-Vitro Cytotoxicity Assay
In-vitro cytotoxicity of free IDA or free DOX, IDA NPs or DOX NPs, and blank NPs were
conducted in various sensitive and resistant cell lines. The IC50 values of different IDA or DOX
formulations are listed in Table 2. IDA NPs showed comparable cytotoxicity with free IDA in
most of the cell lines tested. In some resistant cell lines (e.g. P388/ADR), although the
difference in IC50 values was statistically significant, the cytotoxicity of IDA NPs was only
1–2 fold lower than that of free IDA. In contrast, the IC50 values of DOX NPs were almost 10-
fold lower than that of free DOX in P388/ADR cell line. In the sensitive cell line P388, DOX
NPs showed equivalent cytotoxicity to free DOX as expected (p = 0.13). Blank NPs were
shown to be cytotoxic when the drug equivalent NP concentration was about 1000 nM.
Cellular Uptake of Free IDA and IDA NPs
Cellular uptake of free IDA and IDA NPs were performed in both sensitive HL-60 and resistant
HL-60/VCR cell lines. After a period of 4 hr incubation, a concentration dependent increase
in the cell-associated fluorescence intensity was observed for both free IDA and IDA NPs in
both cell lines (Figure 5). There was little or no difference between free IDA and IDA NPs
within each cell line. More notably, there was no or little statistical difference in the cell-
associated fluorescence for free IDA and IDA NPs between the HL-60 (Figure 5A) and HL-
60/VCR (Figure 5B). For example, at an IDA concentration of 25 nM, the cell-associated
fluorescence intensity of free IDA and IDA NPs was 75 ± 5 and 115 ± 42 in HL-60, respectively,
and 98 ± 7 and 180 ± 32 in HL-60/VCR, respectively. These data suggest that free IDA may
not be strongly effluxed from the Pgp-overexpressing HL-60/VCR cell line. This is in sharp
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contrast to our previous studies in Pgp-overexpressing human ovarian carcinoma NCI/ADR-
RES cell line, wherein greater than 15-fold DOX remained in the Pgp cells for DOX NPs as
compared to free DOX after 4 hr of efflux [18].
Visualizing Cellular Uptake of IDA or DOX NPs
Cell uptake of free IDA and DOX, and their NPs were visualized with the CytoViva Microscope
System. The uptake rate of free IDA was faster than that of free DOX, which is due to its higher
lipophilicity. The extent and rate of uptake for both NP formulations was high as after 10 min,
significant red fluorescence of DOX was seen in most of the nuclei in MDA-MB-468 cells.
However, and in stark contrast, the fluorescence of IDA was seen every where in the cell except
the nucleus (Figure 6).
In-Vivo Animal Efficacy Studies
In study 1, the treatment with free IDA and IDA NPs were ineffective in inhibiting the growth
of the HCT-15 human colon tumor cells at the lower doses of 1.0 and 0.67 mg/kg/injection.
At higher doses of 2.25 and 1.5 mg/kg/injection, both free IDA and IDA NPs treatment resulted
in more than five of ten mice death within 27 days. In the study 2, free IDA and IDA-STS NPs,
and free IDA and IDA-STS PEG NPs were equally effective against the P388 murine leukemia
in CD2F1 mice when administered i.v. at doses of 1.5 and 1.0 mg/kg/injection. At the higher
dose of 2.25 mg/kg/injection, the maximum losses in average body weight of the mice were
16.1% (3.7 g) and 26.5% (6.3 g), respectively, in free IDA and IDA-STS PEG NPs treatment
groups. At the lower dose of 0.67 mg/kg/injection, the difference in survival time between free
IDA and IDA-STS NPs treatment was only one day (data not shown).
In the study 3, the % ILS after i.p. treatment with DOX NPs was found to be statistically
significant when compared with DOX PEG NPs, blank NPs, and free DOX in the P388/ADR
murine leukemia model in male CD2F1 mice at dose of 3.5 mg/kg/injection given with the
treatment schedule of q4d×3 (Figure 7). This treatment resulted in a median day of death of
20 days and ILS value of 67% for DOX NPs, 16.5 days and 38% for DOX PEG NPs, 14.5 days
and 21% for free DOX, and 11 days and −8% for blank NPs, respectively. DOX PEG NPs and
free DOX were equally effective, and as expected, treatment with blank NPs was ineffective.
At dose of 5.3 mg/kg/injection, DOX NPs was found to be statistically significant when
compared with blank NPs (p = 0.0497), or approached statistically significant compared with
DOX PEG NPs (p= 0.0835); while at dose of 8.0 mg/kg/injection, there was no survival
difference between DOX NPs and the other groups, and the median day of death for all groups
ranged from 12.5 to 14.5 days.
DISCUSSION
In the present study, IDA NPs and DOX NPs were engineered using a microemulsion precursor
method previously described by the Mumper group [19]. This method provides many
advantages including formulation adaptability to several different excipients, reproducibly
engineered and well defined solid NPs (<100 nm), and no need for expensive and/or damaging
high-torque mechanical mixing, microfluidization, or homogenization. Emulsifying wax, Brij
78, Vitamin E TPGS and together with the ion-pairing complex were utilized to form a warm
oil-in-water microemulsion precursor, which solidified to SLNs upon direct cooling. This
microemulsion precursor method allowed instantaneous and reproducible formation of both
IDA and DOX NPs, with exhibited diameters around or below 100 nm, small PI (< 0.3), high
entrapment efficiency (> 80%) and homogenous size distribution. The zeta potential of both
SLNs was slightly negative, range from −5 to −15 mV. A 15-day physical stability test of the
IDA NPs at 4°C was also conducted and no statistical difference was found when comparing
the particle size over time (data not shown).
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Particle size is a very important parameter for characterizing the physicochemical properties
of SLNs. Since NPs with large size will usually be taken up by liver, spleen and other parts of
the reticuloendothelial system (RES) in-vivo, particles with size less than 100 nm in diameter
and a uniform size distribution are preferred for tumor targeting [20]. In addition to particle
size, particle surface properties will also affect particle uptake route [21]. Since NPs with more
hydrophobic surface will preferentially be taken up by liver, followed by spleen and lungs,
presentation of a more hydrophilic surface is desired [22]. Therefore, insertion of hydrophilic
PEG groups on the surface is a common strategy to enhance the hydrophilicity of the particle
surface [23]. In our study, DOX PEG NPs were prepared to enhance in-vivo performance.
However, the results showed that DOX PEG NPs were less effective in ILS than non-pegylated
DOX NPs in the P388/ADR CD2F1 mouse model, which may be due to reduced cell uptake
of the pegylated formulation (Figure 7).
To neutralize the cationic charge and enhance entrapment of IDA and DOX hydrochloride salt
forms, counter-ions such as STDC and STS were employed. STDC and STS were effective
counter-ions for IDA and DOX in our SLN formulations. Titration of an aqueous solution of
IDA or DOX with aqueous solution of STDC or STS resulted in immediate formation of ion-
pair complex as red precipitates. During this complexation process, more than 95% of the drugs
could ion-pair with counter-ions, which was very efficient. The obtained ion-paired precipitate
was isolated by centrifugation and was soluble in ethanol. This counter-ion strategy was also
employed previously by the Gasco group [14]. The Gasco group used decyl phosphate or
hexadecyl phosphate to form ion-pairs with DOX or IDA hydrochloride and increase the
entrapment of these drugs in SLNs. Although the group achieved a relatively high loading of
IDA and DOX up to 7% and 8.4% (w/w) and low drug release rate (0.1% in 2 hr) when the
SLNs were placed in water, however, ideally the release study should be performed in PBS
instead of water, which is biologically more relevant and also provides the necessary pH and
ionic strength to test the ability of the ion-pairing agent to retain the drug in the SLNs. The
IDA and DOX SLNs in the present studies had a loading capacity up to 10% (w/w), and the
release rate for IDA and DOX from NPs made with STDC as the ion-pairing agent was 100%
in 6 hr in PBS at 37°C. In contrast, the release rate for DOX from NPs made with STS as the
ion-pairing agent was 84% in 24 hr (data not shown). The slower release rate of drug from NPs
made with STS as the ion-pairing agent is most likely due to the enhanced stability of the STS
ion-pair complex in PBS as compared to the STDC ion-pair complex.
IDA or DOX SLNs have also been formulated to address Pgp-mediated MDR by several other
research groups. Wong et al. [15] prepared DOX SLNs with a drug entrapment efficiency of
60–80% and particle size ranging from 80–350 nm. Treatment of MDR cells with their DOX
SLNs resulted in an over 8-fold increase in cell death when compared to DOX solution
treatment at equivalent doses. In comparison, the DOX NPs in the present studies had increased
entrapment efficiency, smaller and more monodisperse particle size, and almost a 10-fold
greater cytotoxicity in a Pgp-overexpressing cell line P388/ADR. Furthermore, at the dosage
of 3.5 mg/kg/injection to our P388/ADR mouse model, the median survival time was 20 days
after DOX NP treatment and only 14.5 days after free DOX treatment, which significantly
improved therapeutic effect in this MDR mouse model. In sharp contrast, IDA NPs showed
comparable cytotoxicity with free IDA in most of the cell lines tested in-vitro. IDA NPs were
also equally effective as free IDA in-vivo in P388 mouse model and ineffective in-vivo in
HCT-15 mouse model. The Pgp expression in P388/ADR and HCT-15 cells and lack thereof
in P388 cells was confirmed by western blot analysis (Figure 4). Our findings are in agreement
with the previous report from Nancy and co-workers [17]. The authors formulated IDA
liposomes to improve its antitumor activity. However, the results demonstrated that neither
free IDA nor the IDA liposome formulation was therapeutically active in-vivo in resistant P388/
ADR or MDA435LCC6/MDR1 models.
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The mechanism responsible for the different cytotoxic activity of IDA NPs and DOX NPs
versus free drug observed in Pgp-overexpressing cells both in-vitro and in-vivo remains to be
addressed, although the models applied were different (HCT-15 cell model for IDA and P388/
ADR cell model for DOX, respectively). The compositions of excipients in both NP
formulations were the same except for very slight differences in the amount of the ion-pairing
agent used in the formulations. Both IDA and DOX belong to the anthracycline family and
have the same amino sugar moiety, daunosamine, with a pKa of 8.4, which bears the positive
electrostatic charge localized at the protonated amino nitrogen. Thus, both drugs should exhibit
similar electrostatic interactions with cell membrane [4]. However, IDA has a hydrogen atom
in position 14, where DOX has a hydroxyl group attached. Furthermore, IDA does not have
the methoxy group at position 4 (Figure 1A), which results in significantly increased
lipophilicity and cell permeability as compared with DOX [24].
The molecular mechanism of IDA action does not seem to differ significantly from that of
DOX. Both drugs accumulate in the nucleus and intercalate into DNA, which seems to be the
main locus of activity. However, another interesting finding in these studies was the difference
in the intracellular localization of IDA and DOX in sensitive cells after 10 min. Whereas IDA
was found largely extra-nuclear after 10 min, DOX was almost entirely intranuclear. This
observation was supported by Zohreh et al. [25], who found the binding affinity of DOX to
chromatin was higher than that of IDA; therefore, higher aggregation of chromatin with DOX
occurred. They also suggested that the weaker interaction of IDA with chromatin is possibly
attributed to its higher lipophilic nature.
It should be kept in mind that the activity of a drug depends largely upon its intracellular
concentration, and specifically for IDA and DOX the nuclear concentration, which is basically
determined by the kinetics of its influx and efflux of the drug across cell membrane. The influx
rate is greatly affected by the lipophilicity of the drug, while the efflux rate is correlated with
Pgp and MRP associated MDR. Marbeuf-Gueye et al. [26] have demonstrated that the relative
drug resistance of anthracyclines poorly correlated with drug efflux kinetics in Pgp-expressing
cells, which indicates that the influx rate may be the more important contributor to the
intracellular concentration for anthracyclines. The IDA cell uptake studies in both sensitive
HL-60 and resistant HL-60/VCR cell lines demonstrated that the cellular uptake of IDA was
comparable for both IDA NPs and free IDA. In addition, no significant difference in the cellular
uptake of IDA was found between the sensitive and resistant cell lines (Figure 5), which
suggests that the increased lipophilicity of IDA may help circumvent MDR by the influx-
governed mechanism and thereby enhance its chemotherapeutic efficacy. Similar results were
previously reported by Carole et al. [27]. They demonstrated that the uptake rate of IDA was
much higher than the efflux rate mediated by Pgp, which may be a main factor in the improved
IDA cytotoxicity observed in MDR cells in-vitro. In contrast, after treatment of Pgp-
overexpressing human ovarian carcinoma cell line NCI/ADR-RES with our DOX-STS NPs,
greater than 15-fold DOX remained in the Pgp cells compared to free DOX [18]. The
mechanism responsible for increased cellular uptake of our DOX SLNs may be mediated by
the endocytosis pathway described earlier [10]. Wong et al. [15] also proposed two possible
mechanisms of cytotoxicity for DOX SLNs: 1) DOX is released from DOX SLNs outside the
cells and works like free DOX, but its cytotoxicity is enhanced by NPs; 2) DOX is carried by
NPs into the cells and released inside the cells, resulting in higher cytotoxicity. They also
suggested that the mechanisms of SLNs responsible for reversal of MDR activities are
diversified and probably vary from one drug carrier to another. Since Pgp efflux is an energy
dependent process, intracellular ATP levels were also investigated. In previously studies by
our group, it was found that the surfactants Brij 78 and Vitamin E TPGS inhibited Pgp (as
evidenced by increased calcein AM influx), but only Brij 78 depleted ATP [18]. It also should
be noted that cell nucleus is the major target of anthracyclines, and it has been demonstrated
that the nuclear membrane also expresses Pgp to prevent drug penetration into the cell nuclei
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[28]. SLNs may be able to overcome this possible source of drug resistance as well, although
the mechanism is not fully understood.
CONCLUSIONS
The engineered IDA and DOX SLNs from warm microemulsion precursors were manufactured
in a one-vessel procedure that does not require high-torque mechanical mixing, and were
physically stable with diameters of less than 100 nm at least over 15 days stored at 4°C. In-
vitro cytotoxicity studies revealed that the IC50 value of DOX NPs was almost 10-fold lower
than that of free DOX in resistant P388/ADR cells (p = 0.01), whereas IDA NPs had comparable
IC50 values as free IDA in all the cell lines tested. In the in-vivo P388/ADR leukemia mouse
model, at the dose level of 3.5 mg/kg, the median survival time of DOX NPs was 20 days,
which was significantly higher than that of free DOX (14.5 days), or untreated or placebo NPs
(11 days). However, free IDA and IDA NPs were equally effective in P388 leukemia in-vivo
mouse model, as well as in HCT-15 in-vivo mouse model. Unlike free DOX, free IDA remained
active against various Pgp-overexpressing cell lines. This is probably due to the more lipophilic
properties of IDA which allows greater cell accumulation and retention of IDA. The present
studies show that our SLNs may offer potential to deliver anticancer drugs for the treatment
of Pgp-mediated MDR in leukemia; however, selection of target drug may be very important.
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Chemical structures of (A) IDA and DOX and; (B) the IDA-STS and DOX-STS complexes.
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IDA-STS ion-pair complex formation upon mixing of IDA and STS aqueous solutions. IDA
ion-pair complex precipitates were formed upon mixing different molar ratios of IDA and STS
aqueous solutions. After precipitation, the ion-pair complex was centrifuged, and the
concentrations of IDA in the supernatants were measured. The % of IDA ion-paired with STS
was calculated as described in the Methods section. Results are expressed as mean ± SD (n =
3).
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Characterization of concentrated IDA-STDC NPs. IDA-STDC NPs with concentrations
ranging from 240 µg up to 600 µg IDA/mL were engineered by decreasing the volume of
aqueous phase in the warm o/w microemulsion while keeping the composition of oil phase (oil
+ surfactant + drug + ion-pairing agent) constant. Particle size, polydispersity index (PI), and
the total weight of NPs (w/v) were measured. The total weight of NPs (w/v) was calculated as
follows: The total weight of NPs (w/v) = [mass of the oil phase (oil + surfactant + drug + ion-
pairing agent), µg] / [volume of NPs, mL]. Results of particle size measurement are expressed
as mean ± SD (n = 3).
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Western blotting detection of Pgp in P388, P388/ADR, and HCT-15 cell lines. Forty to sixty
micrograms of protein of each cell lysate was isolated using a 10% SDS/PAGE gel.
Immunoblotting was performed using Mdr-1/Pgp antibody, followed by goat anti-mouse IgG-
HRP. The images were then developed using enhanced chemiluminescence. β-actin was used
as the loading control. Lanes 1–3: low protein load; Lanes 4–6: high protein load.
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Cellular uptake of free IDA and IDA NPs in (A) HL-60 and; (B) HL-60/VCR cell lines. Tested
articles were added to a 12-well plate (7.5×105 cells/well) and incubated at 37°C for 4 hr. Cells
were then transferred to 15 mL graduated tubes and centrifuged. The medium was then
aspirated and replaced with fresh medium. Cell-associated fluorescence was measured at the
excitation and emission wavelengths of 485 ± 20 and 545 ± 10 nm, respectively. Results are
expressed as mean ± SD (n = 3). (* p < 0.05, ** p < 0.01)
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Cellular uptake of free IDA or free DOX, and drug NPs in MDA-MB-468 cell line. Cells were
first plated onto glass slides, and then 10 µL of tested articles were dispersed on glass slides
and covered with coverslips. After 10 min, cellular uptake pictures were taken by CytoViva
microscope at room temperature: (A) Free DOX; (B) DOX NPs; (C) Free IDA; (D) IDA NPs.
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Antitumor activity of free DOX and DOX NPs in mice bearing P388/ADR leukemia model.
Survival curves were derived from the following different treatment groups in male CD2F1
mice inoculated i.p. with 105 P388/ADR cells and treated 24 hr later at the dose of 3.5 mg/kg/
injection on a q4d × 3 treatment schedule: (♦) control; (□) DOX NPs; (■) DOX PEG NPs; (◊)
blank NPs; (*) free DOX. The number of 25-day survivors, median day of death, and Increase
in Life-Span (ILS) based on median day of death were recorded.
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Table 1







IDA-STDC NPs 79.7 ± 0.2 0.112 ± 0.035 −5.7 ± 0.6 82 ± 3
IDA-STS NPs 94.7 ± 0.2 0.213 ± 0.057 −13.7 ± 2.1 85 ± 5
DOX-STS NPs 104.2 ± 1.1 0.221 ± 0.071 −14.8 ± 1.2 86 ± 6
Blank NPs 94.4 ± 0.2 0.097 ± 0.022 −10.3 ± 1.7 N/A
N/A: Not Available
*
The standard deviation for each particle size is the standard deviation for the mean of three independent measurements.
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